News

Although SGLT2 inhibitors have become standard in the management of heart failure with preserved and reduced ejection fraction, their use in patients with ATTR…

AbstractWe report a case of dual amyloidosis with Alzheimer's disease and wild-type transthyretin (ATTRwt) amyloidosis. A 76-year-old man with Alzheimer's disease…

Key takeaways:Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis.Regardless of cutoffs, vutrisiran also…

Last month, March 2025, the CGTLive® team was diligently tracking the FDA's activities related to the development of cell and gene therapies for the treatment of…

Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

AbstractClinical genetic testing often takes days to weeks, but rapid, affordable tests during outpatient visits could significantly benefit patients. This is…

"More than a century ago, Dr. Alois Alzheimer described the brain changes in a younger woman who had passed away from what we now call Alzheimer's disease,"…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…